Burkitt lymphoma of the ovary: a case report and literature review. 2013

Noriko Miyazaki, and Yoichi Kobayashi, and Yoshiko Nishigaya, and Mai Momomura, and Hironori Matsumoto, and Mitsutoshi Iwashita
Department of Obstetrics and Gynecology, Kyorin University School of Medicine, Mitaka, Japan.

We report an extremely rare case of primary ovarian Burkitt lymphoma. A 15-year-old girl was referred to our department because of persistent constipation and abdominal distension. Abdominal computed tomography and magnetic resonance imaging revealed a 10-cm-diameter solid tumor located on the right side of the uterus. Serum lactate dehydrogenase and carbohydrate antigen-125 levels were elevated at 3250 IU/L and 235.7 U/mL, respectively. Initially, ovarian dysgerminoma was suspected, but poor performance and progressive disease were suggestive of malignant lymphoma. However, bone marrow aspiration and ascitic fluid cytology findings were not indicative of lymphoma. Laparotomy was performed to confirm pathology. On laparotomy, the right ovary was firm and enlarged, but the uterus and left ovary were normal. Diffuse thickness of retroperitoneal space was observed. Right salpingo-oophorectomy was performed, and the tumor was diagnosed as Burkitt lymphoma. Although intensive chemotherapy was administered, the patient died 171 days after the initial operation.

UI MeSH Term Description Entries
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D002051 Burkitt Lymphoma A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative. African Lymphoma,Burkitt Cell Leukemia,Burkitt Tumor,Lymphoma, Burkitt,Burkitt Leukemia,Burkitt's Leukemia,Burkitt's Lymphoma,Burkitt's Tumor,Leukemia, Lymphoblastic, Burkitt-Type,Leukemia, Lymphocytic, L3,Lymphocytic Leukemia, L3,Burkitts Leukemia,Burkitts Lymphoma,Burkitts Tumor,L3 Lymphocytic Leukemia,L3 Lymphocytic Leukemias,Leukemia, Burkitt,Leukemia, Burkitt Cell,Leukemia, Burkitt's,Leukemia, L3 Lymphocytic,Lymphoma, African,Lymphoma, Burkitt's,Tumor, Burkitt,Tumor, Burkitt's
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D017809 Fatal Outcome Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept. Fatal Outcomes,Outcome, Fatal,Outcomes, Fatal
D019008 Drug Resistance, Neoplasm Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures. Antibiotic Resistance, Neoplasm,Antineoplastic Drug Resistance,Drug Resistance, Antineoplastic,Antineoplastic Agent Resistance,Neoplasm Drug Resistance,Resistance, Antineoplastic Agent,Resistance, Antineoplastic Drug

Related Publications

Noriko Miyazaki, and Yoichi Kobayashi, and Yoshiko Nishigaya, and Mai Momomura, and Hironori Matsumoto, and Mitsutoshi Iwashita
June 1970, Indian journal of cancer,
Noriko Miyazaki, and Yoichi Kobayashi, and Yoshiko Nishigaya, and Mai Momomura, and Hironori Matsumoto, and Mitsutoshi Iwashita
December 2017, Medicine,
Noriko Miyazaki, and Yoichi Kobayashi, and Yoshiko Nishigaya, and Mai Momomura, and Hironori Matsumoto, and Mitsutoshi Iwashita
February 2021, Physiological reports,
Noriko Miyazaki, and Yoichi Kobayashi, and Yoshiko Nishigaya, and Mai Momomura, and Hironori Matsumoto, and Mitsutoshi Iwashita
January 2022, International journal of clinical and experimental pathology,
Noriko Miyazaki, and Yoichi Kobayashi, and Yoshiko Nishigaya, and Mai Momomura, and Hironori Matsumoto, and Mitsutoshi Iwashita
September 2023, Cureus,
Noriko Miyazaki, and Yoichi Kobayashi, and Yoshiko Nishigaya, and Mai Momomura, and Hironori Matsumoto, and Mitsutoshi Iwashita
August 2019, Medwave,
Noriko Miyazaki, and Yoichi Kobayashi, and Yoshiko Nishigaya, and Mai Momomura, and Hironori Matsumoto, and Mitsutoshi Iwashita
April 2012, Quintessence international (Berlin, Germany : 1985),
Noriko Miyazaki, and Yoichi Kobayashi, and Yoshiko Nishigaya, and Mai Momomura, and Hironori Matsumoto, and Mitsutoshi Iwashita
January 2018, Acta medica Lituanica,
Noriko Miyazaki, and Yoichi Kobayashi, and Yoshiko Nishigaya, and Mai Momomura, and Hironori Matsumoto, and Mitsutoshi Iwashita
December 2012, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons,
Noriko Miyazaki, and Yoichi Kobayashi, and Yoshiko Nishigaya, and Mai Momomura, and Hironori Matsumoto, and Mitsutoshi Iwashita
December 1975, Gynecologic oncology,
Copied contents to your clipboard!